Macrocyclic compounds that inhibit MCL-1 protein
US11279712B2 · kind B2 · utility
0Cited by
10References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 27, 2018 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Aug 27, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7068
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.